Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRIBAL

Financiado

Cerrado

A TRranslational approach to Identify Biomarkers for Asthma and Lung function im...

A TRranslational approach to Identify Biomarkers for Asthma and Lung function impairment Asthma is a chronic inflammatory disease of the airways that cause symptoms like wheezing and breathlessness. In children, asthma is the most common chronic disease and according to the WHO, more than 300 million people are affect... ver más

29/02/2024

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-02-29

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

1.50M€ | Lider

EL HORREO HEALTHY FOOD

192.76K€ | Participante

Proyectos interesantes

DPI2015-68820-R

Medical Technol...

Data Science

235K€ Cerrado

BREATH

Medical Technol...

Data Science

71K€ Cerrado

CNS2023-144357

Medical Technol...

Public Health

200K€ Cerrado

RESPIRE-EXCEL

Medical Technol...

Data Science

Cerrado

AsthmaPhenotypes

Medical Technol...

Data Science

2M€ Cerrado

SAF2017-83417-R

Medical Technol...

Data Science

171K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 75 meses Fecha Inicio: 2017-11-17
Fecha Fin: 2024-02-29

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Asthma is a chronic inflammatory disease of the airways that cause symptoms like wheezing and breathlessness. In children, asthma is the most common chronic disease and according to the WHO, more than 300 million people are affected globally. There is no curative treatment available. Persistence of childhood asthma into adult life is associated with lung function impairment and increased risk of chronic obstructive pulmonary disease, COPD. Evidence is now emerging that adult diseases, like COPD, may have their origin early in life. However, there are no established biomarkers that can accurately monitor asthma progression or predict development of COPD in adults. In this TRIBAL project, I will capitalize on rich longitudinal data and repeated bio-sampling from the Swedish BAMSE study, a world-leading population-based birth cohort of 4,089 participants with a new 24-year follow-up starting in 2017. A key aim with the new follow-up is to identify young adults in their 20s with persistent asthma and pre-stage COPD by advanced lung function assessment that includes bronchodilator and nitrogen washout tests. In TRIBAL, the unique setup is deep phenotyping of these patients describing different aspects of the respiratory system, as well as molecular characteristics of relevant bio-samples and cells. Disease-related biomarkers and involved mechanisms, from gene to protein, will be identified from early childhood to adulthood. Both the innate and the adapted immune system with detailed cell characterization will be explored in relation to exposure and disease development. Specifically, with this novel approach I will address the time point during childhood when disease processes related to persistent asthma and pre-stage COPD were initiated. The ultimate goal in TRIBAL is to provide new knowledge for targeted preventive efforts in children at risk of adult chronic lung disease, and to identify potential targets for new asthma and COPD drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores